Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Alice Giacomino is active.

Publication


Featured researches published by Alice Giacomino.


PLOS ONE | 2012

Overexpression of CD157 contributes to epithelial ovarian cancer progression by promoting mesenchymal differentiation.

Simona Morone; Nicola Lo-Buono; R. Parrotta; Alice Giacomino; Giulia Nacci; Alexey Larionov; Paola Ostano; Maurizia Mello-Grand; Giovanna Chiorino; Erika Ortolan; Ada Funaro

Epithelial ovarian carcinoma (EOC) is an aggressive tumor often diagnosed at an advanced stage, when there is little or no prospect of cure. Despite advances in surgical and chemotherapeutic strategies, only marginal improvements in patient outcome have been obtained. Hence, unraveling the biological mechanisms underpinning EOC progression is critical for improving patients’ survival. Recently, we reported that CD157 (an ectoenzyme regulating leukocyte diapedesis) is expressed in EOC and that high expression of the molecule is negatively correlated with the disease outcome in patients. Here, we demonstrate that forced overexpression of CD157 in OVCAR-3, TOV-21G, A2780 and OV-90 ovarian cancer cell lines promotes morphological and phenotypic changes characterized by disruption of intercellular junctions, downregulation of epithelial markers and upregulation of mesenchymal ones. These changes in cell shape and phenotype bring to reduced sensitivity to anoikis, increased anchorage-independent growth, cell motility and mesothelial invasion. Conversely, knockdown of CD157 in OV-90 and OC314 cells reverts the mesenchymal phenotype and reduces the cells’ migratory potential. Transcriptome profiling analysis highlighted 378 significantly differentially expressed genes, representing the signature of CD157-overexpressing OVCAR-3 and OV-90 cells. The modulation of selected genes translates into alteration of protein expression that give cells a highly malignant phenotype. The overall picture deduced from the analysis of the modulated transcripts is that high expression of CD157 strengthens a number of biological processes favoring tumor progression (including development and cell motility), and weakens several biological processes hindering tumor progression (such as apoptosis, cell death and response to stress). Together, these findings implicate CD157 in the progression of EOC to metastatic disease and suggest that CD157 may represent a valuable therapeutic target.


Journal of Biological Chemistry | 2014

Binding of CD157 Protein to Fibronectin Regulates Cell Adhesion and Spreading

Simona Morone; Stefania Augeri; Massimiliano Cuccioloni; Matteo Mozzicafreddo; Mauro Angeletti; Nicola Lo Buono; Alice Giacomino; Erika Ortolan; Ada Funaro

Background: Surface CD157 modulates leukocyte and ovarian cancer cell adhesion and migration through the interaction with an unknown ligand. Results: CD157 binds heparin-binding domains of numerous extracellular matrix proteins with high affinity. Conclusion: The interaction of CD157 with extracellular matrix proteins is instrumental in the regulation of cell adhesion. Significance: These findings provide valuable insights into the biological mechanism responsible for the nonenzymatic functions of CD157. CD157/BST-1 behaves both as an ectoenzyme and signaling receptor and is an important regulator of leukocyte trafficking and ovarian cancer progression. However, the molecular interactions underpinning the role of CD157 in these processes remain obscure. The biological functions of CD157 and its partnership with members of the integrin family prompted us to assume the existence of a direct interaction between CD157 and an unknown component of the extracellular matrix. Using solid-phase binding assays and surface plasmon resonance analysis, we demonstrated that CD157 binds fibronectin with high affinity within its heparin-binding domains 1 and 2. Furthermore, we found that CD157 binds to other extracellular matrix proteins containing heparin-binding domains. Finally, we proved that the CD157-fibronectin interaction occurs with living cells, where it elicits CD157-mediated cell responses. Indeed, knockdown of CD157 in Met-5A mesothelial cells changed their morphology and cytoskeleton organization and attenuated the activation of intracellular signaling pathways triggered by fibronectin. This led to impaired cell spreading and adhesion to selected extracellular matrix proteins. Collectively, these findings indicate a central role of CD157 in cell-extracellular matrix interactions and make CD157 an attractive therapeutic target in inflammation and cancer.


Scientific Reports | 2017

Human canonical CD157/Bst1 is an alternatively spliced isoform masking a previously unidentified primate-specific exon included in a novel transcript

Enza Ferrero; Nicola Lo Buono; Simona Morone; R. Parrotta; Cecilia Mancini; Alice Giacomino; Stefania Augeri; Antonio Rosal-Vela; Sonia García-Rodríguez; Mercedes Zubiaur; Jaime Sancho; Alessandra Fiorio Pla; Ada Funaro

CD157/Bst1 is a dual-function receptor and β-NAD+-metabolizing ectoenzyme of the ADP-ribosyl cyclase family. Expressed in human peripheral blood neutrophils and monocytes, CD157 interacts with extracellular matrix components and regulates leukocyte diapedesis via integrin-mediated signalling in inflammation. CD157 also regulates cell migration and is a marker of adverse prognosis in epithelial ovarian cancer and pleural mesothelioma. One form of CD157 is known to date: the canonical sequence of 318 aa from a 9-exon transcript encoded by BST1 on human chromosome 4. Here we describe a second BST1 transcript, consisting of 10 exons, in human neutrophils. This transcript includes an unreported exon, exon 1b, located between exons 1 and 2 of BST1. Inclusion of exon 1b in frame yields CD157-002, a novel proteoform of 333 aa: exclusion of exon 1b by alternative splicing generates canonical CD157, the dominant proteoform in neutrophils and other tissues analysed here. In comparative functional analyses, both proteoforms were indistinguishable in cell surface localization, specific mAb binding, and behaviour in cell adhesion and migration. However, NAD glycohydrolase activity was detected in canonical CD157 alone. Comparative phylogenetics indicate that exon 1b is a genomic innovation acquired during primate evolution, pointing to the importance of alternative splicing for CD157 function.


Oncotarget | 2018

Soluble CD157 in pleural effusions: a complementary tool for the diagnosis of malignant mesothelioma

Stefania Augeri; Stefania Capano; Simona Morone; Giulia Fissolo; Alice Giacomino; Silvia Peola; Zahida Drace; Ida Rapa; Silvia Novello; Marco Volante; Luisella Righi; Enza Ferrero; Erika Ortolan; Ada Funaro

Background CD157/Bst1 glycoprotein is expressed in >85% of malignant pleural mesotheliomas and is a marker of enhanced tumor aggressiveness. Results In vitro, mesothelial cells (malignant and non-malignant) released CD157 in soluble form or as an exosomal protein. In vivo, sCD157 is released and can be measured in pleural effusions by ELISA. Significantly higher levels of effusion sCD157 were detected in patients with malignant pleural mesothelioma than in patients with non-mesothelioma tumors or with non-malignant conditions. In our patient cohort, the area under the receiver-operating characteristic curve for sCD157 that discriminated malignant pleural mesothelioma from all other causes of pleural effusion was 0.685, cut-off (determined by the Youden Index) = 23.66 ng/ml (62.3% sensitivity; 73.93% specificity). Using a cut-off that yielded 95.58% specificity, measurement of sCD157 in cytology-negative effusions increased sensitivity of malignant pleural mesothelioma diagnosis from 34.42% to 49.18%. Conclusions Evaluation of soluble CD157 in pleural effusions provides a diagnostic aid in malignant mesothelioma. Methods Soluble CD157 (sCD157) was detected biochemically in culture supernatants of malignant and non-malignant mesothelial cells, and in pleural effusions from various pathological conditions. An ELISA system was established to measure the concentration of sCD157 in fluids, and extended to analyze sCD157 in pleural effusions from a cohort of 295 patients.


International Journal of Gynecological and Obstetrical Research | 2013

Biological role, clinical significance and potential therapeutic applications of CD157 in ovarian cancer

Simona Morone; Ada Funaro; Alice Giacomino; R. Parrotta; R. Arisio; D. Katsaros; N. Biglia; G. Chiorino; Ida Rapa; Marco Volante; Erika Ortolan

Ovarian cancer is the leading cause of gynecologic cancer-related morbidity and mortality owing to the difficulty in detecting early-stage disease. Despite advances in surgical and chemotherapeutic strategies, only marginal improvement in patient outcome has been achieved. Hence, understanding the biological mechanisms underlying ovarian cancer development and progression is critical for its treatment. We reported that CD157 (also known as BST-1), a NAD-metabolizing ectoenzyme regulating leukocyte diapedesis in inflammatory conditions, is expressed in approximately 90% of epithelial ovarian cancers and high CD157 expression is associated with poor outcome in patients. Our experimental results showed that CD157 controls ovarian cancer progression by promoting mesenchymal differentiation. The increased aggressiveness associated with tumors with high CD157 can be reverted in vitro by CD157 gene silencing, or by monoclonal antibodies that block CD157. The overall picture inferred from our experimental and clinical findings suggests that CD157 could aid diagnosis by classifying ovarian cancers into molecular subtypes with different outcomes, CD157 could also represent a novel candidate as a target of antibody-based therapies. This review summarizes and assesses recent research into the emerging functions of CD157 in the control of ovarian cancer progression.


Archive | 2012

Ectoenzymes in Epithelial Ovarian Carcinoma: Potential Diagnostic Markers and Therapeutic Targets

Nicola Lo Buono; Simona Morone; R. Parrotta; Alice Giacomino; Erika Ortolan; Ada Funaro

Ovarian cancer is one of the most lethal among the gynaecological malignancies, affecting 12% of women in developed countries (Cannistra, 2004). The lethality of ovarian cancer is primarily attributable to our current inability to detect the disease at an early stage, when it is still limited to the ovary. Therefore, the majority of patients are diagnosed when they have advanced-stage disease. Despite progresses in cytotoxic therapies, only 30% of patients with advanced-stage ovarian cancer survive 5 years after diagnosis. The insidious nature of ovarian cancer stems from its unique biological behaviour: ovarian carcinoma can spread by direct extension to adjacent organs, and exfoliated tumour cells can be transported in peritoneal fluid (Naora et al., 2005). Subsequent implants are characterised by their adhesion to mesothelial cells, migration throughout and invasion of the tumor cells into the omentum and peritoneum. This seeding of the peritoneal cavity is frequently associated with ascites formation. Only secondarily and rather late during the disease progression, are pelvic and para-aortic lymph nodes involved. However, the local peritoneal disease cannot be controlled and remains a factor leading to death (Feki et al., 2009). The cellular processes that lead to local and distant dissemination of ovarian cancer are not fully understood, and the mechanisms of interaction between cancer cells and mesothelium need to be further elucidated to achieve novel information on the biology of this highly aggressive form of cancer and possibly, to identify new potential targets for selective therapeutic strategies. The combined effort of clinicians and researchers has led to the identification of a number of molecules that might facilitate screening, diagnosis, prognosis and monitoring response to treatment or relapse during follow-up. These new molecules might provide specific targets for anti-tumour therapy with antibody-directed treatments, gene therapy or specific inhibitory molecules. An unexpectedly high number of these newly identified molecules have turned out to be cell surface-expressed ectoenzymes. Ectoenzymes are a large, heterogeneous class of membrane proteins whose catalytically active sites face the extracellular environment. The products of their catalytic activities can influence the extracellular environment (for example, several of these products can function as second messengers or regulate the recruitment of cells). Moreover, many ectoenzymes can function


Oncotarget | 2014

CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome

Erika Ortolan; Alice Giacomino; Francesca Martinetto; Simona Morone; Nicola Lo Buono; Enza Ferrero; Giorgio V. Scagliotti; Silvia Novello; Sara Orecchia; Enrico Ruffini; Ida Rapa; Luisella Righi; Marco Volante; Ada Funaro


European Journal of Cancer | 2012

445 CD157 is a Novel Prognostic Marker of Malignant Pleural Mesothelioma Involved in the Control of Tumor Aggressiveness

Alice Giacomino; Simona Morone; R. Parrotta; N. Lo Buono; Ida Rapa; Luisella Righi; Marco Volante; Enrico Ruffini; Erika Ortolan; Ada Funaro


European Journal of Cancer | 2012

441 Involvement of CD157 in the Control of Ovarian Cancer Progression

N. Lo Buono; Simona Morone; R. Parrotta; Alice Giacomino; G. Chiorino; P. Ostano; M. Mello-Grand; Ada Funaro; Erika Ortolan


Journal of Thoracic Oncology | 2011

Clinical and biological significance of CD157 in malignant pleural mesothelioma

Simona Morone; Erika Ortolan; Alice Giacomino; R. Parrotta; N. Lo Buono; Ida Rapa; Luisella Righi; Marco Volante; Enrico Ruffini; S. Demichelis; G. Rovere; Silvia Novello; Fabio Malavasi; Ada Funaro

Collaboration


Dive into the Alice Giacomino's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge